Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Cheng Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, State Key Laboratory of Pharmaceutical Biotechnology, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Src homology-2-containing protein tyrosine phosphatase (PTP) 2 (SHP2) is a pivotal PTP that modulates key cellular processes including proliferation, differentiation, and migration. Its overexpression is implicated in the pathogenesis of various malignancies, highlighting the need for effective SHP2 inhibitors. Herein, we report the design and synthesis of a novel series of thiazolo[5,4-b]pyridine and imidazo[1,2-c]pyrimidine derivatives as SHP2 allosteric inhibitors identified through active fragment splicing. The synthesized compounds exhibited potent SHP2 inhibition, with IC50 values ranging from 9.0 to 34.5 nM. Notably, compound B8 demonstrated superior potency, with an IC50 of 0.04 μM for p-ERK modulation. Compound B8 also displayed favorable drug-like properties and significant antitumor activity in a KYSE520 xenograft mouse model, underscoring its potential as a lead candidate for further development. Our findings provide a foundation for the advancement of SHP2-targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- Beijing Tide Pharmaceutical Co., Ltd., Beijing 100176, China.
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.
ORCID-Profile: Cheng Shi, Zhenming Liu, Liangren Zhang
Förderung
- Natural Science Foundation of Beijing Municipality
- State Key Laboratory of Pharmaceutical Biotechnology
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Shi, C., Zhao, Y., Huang, H., Zhou, J., Lu, D., Chen, Y., Lyu, W., Liu, Z., Wang, H., & Zhang, L. (2025). Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02100
Vancouver
Shi C, Zhao Y, Huang H, Zhou J, Lu D, Chen Y, et al. Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02100
BibTeX
@article{Shi2025,
author = {Shi, Cheng and Zhao, Yanping and Huang, Han and Zhou, Jiaxu and Lu, Dehua and Chen, Yanming and Lyu, Weiping and Liu, Zhenming and Wang, Hongjun and Zhang, Liangren},
title = {Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02100}
}
EUVIMED